Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.55 |
| ▸ | CCR3 | P51677 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823189 | 0.89 | CCR3 (0.57) | HSD11B1EPHX1EPHX2CCR3CNR2 | |
| SCHEMBL5358819 | 0.79 | FAAH (0.85) | CCR3FAAHMEN1KMT2A | |
| SCHEMBL6331510 | 0.77 | CCR3 (0.81) | EPHX1EPHX2CCR3MEN1KMT2A | |
| SCHEMBL6337374 | 0.76 | CCR3 (0.77) | EPHX1EPHX2CCR3 | |
| SCHEMBL5366470 | 0.75 | TACR3 (0.71) | CCR3MEN1KMT2ASIGMAR1 | |
| SCHEMBL5366293 | 0.75 | HTT (0.67) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL7362108 | 0.74 | FAAH (0.72) | HSD11B1FAAHMEN1KMT2APOLB | |
| SCHEMBL6338952 | 0.74 | EPHX2 (0.55) | EPHX1EPHX2CCR3 | |
| SCHEMBL4535118 | 0.73 | EPHX2 (0.72) | EPHX1EPHX2MEN1KMT2A | |
| SCHEMBL13647198 | 0.72 | FAAH (0.72) | HSD11B1FAAHMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | claimed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | claimed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | claimed |
| EP-1140834-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035877-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | disclosed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-09-23 | — | — | US | disclosed |
| US-6759411-B2 | ANTIHISTAMINES, ANTIALLERGENS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-07-06 | — | — | US | disclosed |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-29 | — | — | US | disclosed |
| US-6331545-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1140834-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035877-A1 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186097-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | HSD11B1 1179/4885EPHX1 1245/4885EPHX2 1669/4885 |
| US-20020119980-A1 | Heterocyclic piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR4 | HSD11B1 1179/4885EPHX1 1245/4885EPHX2 1669/4885 |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR3, CCR1, CCR4 | HSD11B1 1509/4885EPHX1 1331/4885EPHX2 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.